These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1746 related articles for article (PubMed ID: 16938815)

  • 1. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
    Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
    Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
    Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
    Luxton G; Hancock SL; Boyer AL
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
    Kassim I; Dirkx ML; Heijmen BJ
    Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
    Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
    Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
    Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
    Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.
    Muren LP; Wasbø E; Helle SI; Hysing LB; Karlsdottir A; Odland OH; Valen H; Ekerold R; Johannessen DC
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1034-41. PubMed ID: 18249502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical aspects of inverse-planned intensity-modulated radiation therapy for prostate cancer: a radiation treatment planner's perspective.
    Parker W; Patrocinio H
    Can J Urol; 2005 Jun; 12 Suppl 2():48-52. PubMed ID: 16018834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.
    Ganswindt U; Paulsen F; Corvin S; Hundt I; Alber M; Frey B; Stenzl A; Bares R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):347-55. PubMed ID: 17236960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients.
    Bayouth JE; Pena J; Culp L; Brack C; Sanguineti G
    Med Dosim; 2008; 33(3):180-90. PubMed ID: 18674682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?
    Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V
    Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk.
    Ahmed RS; Kim RY; Duan J; Meleth S; De Los Santos JF; Fiveash JB
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):505-12. PubMed ID: 15380585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer.
    Fiorino C; Alongi F; Perna L; Broggi S; Cattaneo GM; Cozzarini C; Di Muzio N; Fazio F; Calandrino R
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):29-35. PubMed ID: 19467803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
    O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
    Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.
    Guerrero M; Li XA; Ma L; Linder J; Deyoung C; Erickson B
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):933-9. PubMed ID: 15936580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.